Skip to main content
As we continue to face the global challenge of obesity, which affects 16% of adults worldwide, the search for effective treatments has never been more pressing. Dr. Aaron Dehghan, a seasoned GP at GibMed International Hospital, is at the forefront of this battle, providing insights into the dynamic world of obesity medications redefining patient care.

When Dr. Dehghan began his medical journey in London, Orlistat was the sole option available – a drug whose effectiveness was often debated. Fast forward to today and the scene has transformed dramatically. Dr. Dehghan, now working at our Specialist Medical clinic in Gibraltar, shares that over 200 obesity drugs are under development, reflecting a significant shift in treatment paradigms.

Among the standout medications are Liraglutide (Saxenda), Semaglutide (Ozempic / Wegovy), and Tirzepatide (Zepbound / Mounjaro), each marking a milestone in effectiveness and patient outcomes. Notably, Tirzepatide leads the pack with potential weight loss figures as impressive as 15-20%. “These numbers aren’t just statistics,” Dr. Dehghan emphasises, “they represent real hope for patients, combined with essential lifestyle changes like diet and exercise.”

The fascination with these drugs has soared, partly fueled by media coverage and celebrity endorsements, which has even led to global shortages. Yet, Dr. Dehghan cautions that no treatment is without risks. It’s crucial for patients to take charge of their health and engage in informed discussions with healthcare providers before starting any new medication.

Beyond their weight-reducing capabilities, these drugs show promise in reducing risks associated with obesity, such as diabetes, heart disease and more. Studies like the SELECT trial for Semaglutide are investigating these potential benefits further, pointing to a future where these medications do more than just reduce weight—they improve overall health.

Looking ahead, the horizon is bright with potential developments. Innovations such as Orforglipron, an oral tablet currently in trials, and Retatrutide, a “triple G” drug targeting multiple metabolic pathways, are not just promising; they are the future of obesity care. Dr. Dehghan believes that these advancements will redefine obesity care, offering new hope to patients and healthcare professionals alike.

As we embrace these changes, GibMed International Hospital remains committed to providing the latest medical advancements and patient care. “The landscape of obesity treatment is evolving,” Dr. Dehghan concludes, “and with it, our ability to offer new beginnings to those we serve.”

Stay tuned to our newsletter for more updates on how we’re transforming the future of healthcare, one breakthrough at a time. Together with experts like Dr. Dehghan, we are stepping boldly into a healthier future.


SHARE